Ketolides represent a new generation of macrolide antibiotics. In order to identify the ketolide-binding site on the ribosome, a library of Escherichia coli clones, transformed with a plasmid carrying randomly mutagenized rRNA operon, was screened for mutants exhibiting resistance to the ketolide HMR3647. Sequencing of the plasmid isolated from one of the resistant clones and fragment exchange demonstrated that a single U754A mutation in hairpin 35 of domain II of the E. coli 23S rRNA was sufficient to confer resistance to low concentrations of the ketolide. The same mutation also conferred erythromycin resistance. Both the ketolide and erythromycin protected A2058 and A2059 in domain V of 23S rRNA from modification with dimethyl sulphate, whereas, in domain II, the ketolide protected, while erythromycin enhanced, modification of A752 in the loop of the hairpin 35. Thus, mutational and footprinting results strongly suggest that the hairpin 35 constitutes part of the macrolide binding site on the ribosome. Strong interaction of ketolides with the hairpin 35 in 23S rRNA may account for the high activity of ketolides against erythromycin-resistant strains containing rRNA methylated at A2058. The existence of macrolide resistance mutations in the central loop of domain V and in hairpin 35 in domain II together with antibiotic footprinting data suggest that these rRNA segments may be in close proximity in the ribosome and that hairpin 35 may be a constituent part of the ribosomal peptidyl transferase centre.
Introduction
Ribosome-targeted antibiotics have been used successfully as tools for studying the structure and function of the ribosome. As the size of the drug molecule is significantly smaller than the size of the ribosome, it is commonly assumed that most antibiotics bind close to the functional centres whose activity they inhibit. In fact, some of the main ribosomal functional centres, for example peptidyl transferase, have been mapped using antibiotic probes (reviewed by Noller, 1991) . Therefore, mapping the drug binding sites helps to identify functionally important ribosomal components.
rRNA has been implicated in practically every ribosomal function. Thus, it is not surprising that most of ribosometargeted antibiotics interact with rRNA (Cundliffe, 1990) . The majority of antibiotic binding sites are formed by rRNA segments located distantly in the primary RNA structure but brought together in the tertiary ribosome folding. Studying the interactions of antibiotics with such sites provides useful information about the structural organization of the ribosome. The contacts between antibiotics and rRNA can be revealed using biochemical techniques (such as cross-linking or RNA footprinting) or genetically (by identifying mutations in rRNA that confer resistance to antibiotics). Although neither of these techniques is free from intrinsic problems, convergence of the results obtained by different methods is usually taken as a strong indication of interaction of the drug with a particular site in rRNA. This concept received strong support when the structure of the complex of an aminoglycoside paromomycin with the ribosomal A-site was solved; the NMR data demonstrated decisively that paromomycin interacts specifically with an rRNA segment identified previously by footprinting and mutational analyses (Fourmy et al., 1996) .
Macrolide antibiotics interact with the large ribosomal subunit in the vicinity of the peptidyl transferase centre and inhibit protein synthesis apparently by hindering the growth of the nascent peptide chain and promoting dissociation of peptidyl tRNA from the ribosome (Vazquez, 1975; Menninger and Otto, 1982; Menninger et al., 1994) . The binding site of the best-studied, 14-member-ring macrolide, erythromycin A, includes several positions in domain V of the 23S rRNA where the drug protects positions A2058 and A2059 from chemical modification (Moazed and Noller, 1987; Douthwaite and Aagaard, 1993) (Fig. 1) . Mutations at these two positions and also at positions 2057 and 2611 render cells erythromycin resistant (Sigmund and Morgan, 1982; Sigmund et al., 1984; Ettayebi et al., 1985; Vester and Garrett, 1987) . Furthermore, mono-or dimethylation of A2058 in MLS-resistant strains (MLS stands for macrolides, lincosamides and streptogramin B) is one of the primary mechanisms of erythromycin resistance (for a review, see Weisblum, 1995) .
A new class of macrolide antibiotics, the ketolides, exhibit high activity against MLS-resistant bacterial strains (Agouridas et al., Ednie et al., 1997; Schü lin et al., 1997) . We have investigated interactions of one of the ketolides, HMR3647, with the ribosome and found that HMR3647, as well as erythromycin, interacts not only with domain V of 23S rRNA, but also with rRNA segments in domain II, in the vicinity of the hairpin 35 loop. A mutation in the hairpin 35 confers resistance to erythromycin and ketolide; in addition, both antibiotics affect the accessibility of nucleotides in the hairpin loop to chemical modification. These results show that hairpin 35 is located in the vicinity, and may be a part, of the ribosomal peptidyl transferase centre.
Furthermore, a strong interaction of ketolides with the hairpin 35 region may account for their high activity against erythromycin-resistant bacteria.
Results

Footprinting HMR3647 and erythromycin on the ribosome
Erythromycin and ketolides belong to 14-member-ring macrolide antibiotics, which inhibit the elongation of translation in sensitive bacteria. The L-cladinose sugar moiety at position 3 of erythromycin A aglycone is replaced by a keto group in ketolides (Agouridas et al., 1997) . It has been shown previously that erythromycin protects the A2058 and A2059 positions in domain V of 23S rRNA from modification by dimethyl sulphate (DMS) (Moazed and Noller, 1987; Douthwaite and Aagaard, 1993) . Similarly, ketolide HMR3647 used in this study protects A2058 and A2059 ( Fig. 2A) . However, we also noticed that HMR3647 strongly protects A752 in the loop of hairpin 35 (Egebjerg et al., 1990) in domain II of 23S rRNA ( 
Selection of a ketolide resistance mutation
Point mutations conferring resistance to erythromycin are clustered in domain V of 23S rRNA ( Fig. 1) (Sigmund et al., 1984; Ettayebi et al., 1985; Vester and Garrett, 1987) . The finding that both erythromycin and HMR3647 also interact with domain II encouraged us to look for macrolide resistance mutations in domain II. The pKK3535 plasmid containing the entire rrnB operon under the control of its native P1 and P2 promoters was mutagenized randomly by passing it through a mutator E. coli strain. When the tester E. coli strain JM109 was transformed with the mutagenized pKK3535 and plated onto agar medium containing HMR3647, several resistant colonies appeared. Sequencing 23S rRNA gene in a full-size plasmid isolated from one of the resistant colonies revealed the presence of two mutations closely located in domain II, G638A and U754A. The mutations were segregated from each other by fragment exchange (see Experimental procedures), and the U754A mutation was introduced into pKK3535 to generate pKK754A. As this construct conferred the same level of resistance as the double mutant originally selected (not shown), we concluded that the single point mutation U754A is sufficient to render cells resistant to the ketolide HMR3647.
The U754A mutation confers both ketolide and erythromycin resistance
The effect of U754A mutation on the sensitivity of E. coli to erythromycin or HMR3647 was analysed by a spot test on agar plates or in liquid culture. As can be seen from the expression of the mutant 23S rRNA rendered cells resistant not only to HMR3647, but also to erythromycin. The minimal inhibitory concentration (MIC) of HMR3647 was 20 M for E. coli JM109 cells transformed with pKK3535 and 50 M for cells transformed with pKK754A. The erythromycin MIC was 100 M and 160 M for the cells transformed with pKK3535 or pKK754A respectively. Thus, the mutation in the hairpin 35 conferred resistance to different types of macrolide antibiotics.
23S rRNA with the U754A mutation is incorporated into the active ribosome pool
To verify that ribosomes containing the U754A mutation in 23S rRNA are functional in protein synthesis, the distribution of wild-type and mutant 23S rRNA in different ribosomal fractions was analysed by primer extension (Sigmund et al., 1988; Powers and Noller, 1991) . Polysomes were prepared from the cells transformed with pKK754A, and the ratio of mutant and wild-type rRNA was determined in the fractions corresponding to the 50S subunits, 70S ribosomes and polysomes (Table 1) . Almost three-quarters of the rRNA in the polysomal (trisomes) fraction of translating ribosomes was represented by the mutant rRNA, indicating that 23S rRNA containing the U754A mutation is active in translation. This conclusion is consistent with the observation that, in the absence of antibiotics, the growth rate of cells transformed with pKK754A plasmid was indistinguishable from the growth rate of cells transformed with the wild-type pKK3535, indicating that the U754A mutation does not interfere with normal ribosomal functions.
Discussion
Erythromycin has a single binding site on the ribosome located on the large ribosomal subunit and, at saturation, one ribosome binds one molecule of erythromycin (Taubman et al., 1963; Mao and Putterman, 1969; Ferná ndezMuñoz and Vázquez, 1973) . A combination of genetic and biochemical data strongly implicated the central loop of domain V of 23S rRNA in antibiotic binding. Mutations conferring erythromycin resistance are clustered in the central loop of domain V in a segment of 23S rRNA (positions G2057, A2058, A2059 and C2611) (reviewed by Weisblum, 1995 ; see also Occhialini et al., 1997; Sander et al., 1997) . These mutations, as well as mono-or dimethylation of A2058, decrease the affinity of macrolides to the ribosome (Douthwaite and Aagaard, 1993) . Moazed and Noller (1987) have shown previously that erythromycin protected A2058 and A2059 in the central loop of domain V from DMS modification. Our results confirmed their finding: macrolides, erythromycin and HMR3647 strongly protect A2058 and A2059 ( Fig. 2A) . Unexpectedly, however, the genetic and biochemical evidence described in this paper suggests that a distantly located segment of 23S rRNA may also be directly involved in interaction with macrolide antibiotics. We have shown that mutation of U754 to A in the hairpin 35 in 23S rRNA rendered cells resistant to low concentrations of two macrolide antibiotics, erythromycin and a ketolide HMR3647. Furthermore, similar to Hansen et al. (1998) , we observed a pronounced effect of macrolides on the accessibility of a neighbouring A752 in the loop of the hairpin 35 to chemical modification, where HMR3647 strongly protected A752, while erythromycin markedly increased modification of A752 by DMS. Although, to our knowledge, the effect of erythromycin on modification of A752 has not been discussed previously, published gels (Moazed and Noller, 1987) clearly show enhancement of modification of A752 in the presence of the drug.
The effects of macrolides on the accessibility of nucleotides in the hairpin 35 loop are not limited to A752. When footprinted on the Thermus aquaticus ribosome, HMR3647, but not erythromycin, also protected a position corresponding to the E. coli ⌿746 (data not shown). This region could not be analysed in the E. coli ribosome because of reverse transcriptase stops, which occur at modified nucleotides in ᮊ 1999 Blackwell Science Ltd, Molecular Microbiology, 31, 633-639 Fig. 3 . Ketolide and erythromycin resistance of the cells expressing 23S rRNA with the U754A mutation. Exponential cultures of E. coli cells transformed with pKK754A or pKK3535 grown in the presence of 100 g ml ¹1 ampicillin were diluted to Ϸ5 × 10 3 cfu ml ¹1 , and 20 l aliquots were spotted on agar plates containing 100 g ml ¹1 ampicillin, 100 g ml ¹1 ampicillin and 30 M HMR3647 or 100 g ml ¹1 ampicillin and 140 M erythromycin. Plates were incubated 16 h at 37ЊC. Figs 1B and 2B) ; in the T. aquaticus ribosome, this segment of rRNA is accessible for primer extension analysis. Collectively, our results highlight three positions that may be important for macrolide binding (U754, A752 and ⌿746). However, available data do not allow us to discriminate which of the observed effects reflect a direct RNA-drug interaction and which result from local allosteric effects. It is conceivable, for example, that the U754A mutation in the stem of the hairpin 35 may change the overall conformation of the hairpin loop, making it less favourable for interaction with the antibiotic.
The only other antibiotic known to produce a footprint on A752 is a streptogramin-type antibiotic vernamycin B (Moazed and Noller, 1987) . Macrolides and streptogramin B-type antibiotics are believed to inhibit protein synthesis through a similar mechanism, i.e. by sterically hindering the growth of the nascent peptide chain and promoting dissociation of peptidyl-tRNA (Vazquez, 1975; Menninger and Otto, 1982; Menninger et al., 1994) . Overlapping footprints produced by these antibiotics on 23S rRNA (Moazed and Noller, 1987; our unpublished results) indicate that macrolides and streptogramin B antibiotics may also interact with similar sites on the ribosome, including the central loop of domain V and hairpin 35.
Genetic and biochemical data argue that the macrolide binding site may be composed of the rRNA segments belonging to the central loop of domain V and hairpin 35 of domain II of 23S rRNA. While interactions of erythromycin and HMR3647 with domain V appear to be similar (see Fig. 2A ), their interactions in domain II are notably different. The possible stronger interaction of the ketolide, compared with erythromycin, with hairpin 35 may explain the high activity of ketolides against MLS strains that contain ribosomes with methylated A2058 (Agouridas et al., 1997; Ednie et al., 1997) . A2058 methylation weakens the interaction of macrolides with the ribosome; however, in the case of ketolide (but not erythromycin), a strong interaction of the drug with another part of the binding site (hairpin 35) is sufficient for the binding of the antibiotic.
Convincing biochemical and genetic evidence implicates the central loop of domain V of 23S rRNA as an essential part of the peptidyl transferase centre (reviewed in Garrett and Rodriguez-Fonseca, 1995; Wower et al., 1995) . The existence of macrolide resistance mutations in both the central loop of domain V and hairpin 35, coupled with the simultaneous protection of nucleotides in these two regions by macrolides, suggests the close proximity of hairpin 35 to the peptidyl transferase centre. This notion is supported by cross-linking data, as segment 739-748 of the hairpin 35 was UV cross-linked to region 2609-2618 in the central loop of domain V (Stiege et al., 1983; 1986) . A triple base interaction involving ⌿ 746, G2057 and C2611 has been proposed on the basis of co-variation analysis (Gutell, 1995) , but still awaits experimental confirmation. Hairpin 35 is one of the most conserved secondary structure elements in 23S rRNA and is found even in the minimalist mitochondrial large ribosomal subunit rRNA (Gutell et al., 1993) . The strict evolutionary conservation of this hairpin and the presence of several modified nucleotides in the hairpin loop strongly argue that this segment of 23S rRNA may be directly implicated in ribosomal functions. The proximity of this hairpin to the central loop of domain V suggests that its functions might be related to the ribosomal peptidyl transferase.
Experimental procedures
Reagents, strains and plasmids Ketolide (HMR3647) was from Hoechst Marion Roussel, France. Unlabelled erythromycin was purchased from Sigma; [ 14 C]-erythromycin (specific activity 55 Ci mol ¹1 ) was from DuPont NEN. Dimethyl sulphate was from Aldrich. All the other chemicals were from Fisher Scientific.
E. coli JM109 strain (Yanisch-Perron et al., 1985) (endA1, recA1, gyrA96, thi, hsdR17 (r [FЈ, traD36, proAB, lacI q ZDM15) was used for propagation of the wild-type and mutant plasmids and for drug sensitivity testing. E. coli mutator strain XL1-Red (Stratagene) (endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac, mutD5, mutS, mutT, Tn10(Tet r )) was used for mutagenesis of the pKK3535 plasmid.
Selection of ketolide resistance mutation
The mutator E. coli strain XL-1 Red (Stratagene) was transformed with pKK3535 plasmid (Brosius et al., 1981) . Transformed cells were grown at 37ЊC overnight in LB medium containing 100 g ml ¹1 ampicillin. The total plasmid was isolated and used to transform E. coli JM109. Transformed JM109 cells were plated onto agar medium containing 100 g ml ¹1 ampicillin and 30 M HMR3647. Liquid cultures were grown from individual HMR3647-resistant colonies; plasmids were isolated and used to transform fresh JM109 cells. The sensitivity of transformed cells to HMR3647 was tested by replica plating.
Several plasmids conferring a transferable HMR3647-resistant phenotype were smaller than the original pKK3535 and were not analysed further. One of the plasmids (pKK3535-19), corresponding in size to pKK3535, was used for detailed analysis. Sequencing of the 23S rRNA gene revealed the presence of two mutations, G638A and U754A, in domain II of 23S rRNA. To segregate the two mutations, the SacI-SphI fragment from pKK3535-19, containing both mutations, was first used to replace the corresponding fragment in the plasmid pLK35 (Douthwaite et al., 1989) . The NcoI-NcoI fragment from the resulting plasmid, which contained only the U754A mutation, was introduced into the wild-type pLK35 to produce pLK35/754. Finally, the XbaIBpu1102I fragment from pLK35/754 was used to replace the corresponding fragment in pKK3535. The resulting pKK3535 derivative (pKK754A) contained only the U754A mutation.
The HMR3647 and erythromycin resistance of the U754A
ᮊ 1999 Blackwell Science Ltd, Molecular Microbiology, 31, 633-639 mutant was assayed in a spot test (Powers and Noller, 1990) , in which dilutions of cell cultures transformed with pKK754A or pKK3535 plasmids were spotted onto agar plates containing 100 g ml ¹1 ampicillin and either 140 M erythromycin or 30 M HMR3647. Plates were incubated for 16 h at 37ЊC and photographed.
Testing antibiotic sensitivity in liquid culture was performed by growing overnight cultures of JM109 cells transformed with either pKK3535 or pKK754A in the presence of 100 g ml ¹1 ampicillin, diluting them 1000-fold into fresh medium containing 100 g ml ¹1 ampicillin and different concentrations of either erythromycin or HMR3647, growing for 7 h at 37ЊC and reading the culture optical density at 650 nm.
Distribution of mutant 23S rRNA between the ribosome fractions E. coli JM109 cells transformed with pKK754A plasmids were grown in liquid cultures, and polysomes were prepared by the freeze-thaw method and fractionated by sucrose gradient centrifugation (Ron et al., 1966) . The distribution of mutant rRNA between various ribosomal fractions was assayed by primer extension (Sigmund et al., 1988; Powers and Noller, 1991) using an oligonucleotide primer CCACAAGTCATCC-GCT complementary to the 23S rRNA segment 756-771.
Footprinting of erythromycin and HMR3647 on the 70S ribosome 70S ribosomes were prepared according to the method of Moazed and Noller (1989) , with the only modification that the second wash with 0.5 M NH 4 Cl was omitted. Heat-activated ribosomes (10 pmol) were incubated for 10 min at 37ЊC and for 10 min at 20ЊC in 50 l of buffer (80 mM potassium cacodylate, pH 7.2, 20 mM MgCl 2 , 100 mM NH 4 Cl, 1.5 mM dithiothreitol) containing either erythromycin or HMR3647 at final concentrations 5 or 50 M. Modification with DMS and primer extension analysis was performed according to Stern et al. (1988) .
